BRIEF-Interim data support safety and efficacy of Pharming Group's RUCONEST

Mon Jun 1, 2015 1:19am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

June 1 (Reuters) - Pharming Group NV :

* Announces interim results from the ongoing phase II pediatric clinical trial of RUCONEST

* Interim data from ongoing pediatric clinical trial and results from a clinical immunology study support safety and efficacy of RUCONEST

* Several abstracts presented demonstrate Pharming's ongoing commitment to advance innovative science in Hereditary Angioedema (HAE)

* "These data add to our clinical database and post-marketing experience that demonstrate a very low risk of allergy with rhC1INH exposure" - Chief Operating officer Source text for Eikon: Further company coverage: (Gdynia Newsroom)